Telo Genomics Appoints CEO with 3.7M Options; Clinical Results by Summer 2026
Telo Genomics named John Farlinger CEO and chairman effective March 18, granting him 3.7 million stock options exercisable at $0.055 with 50% vesting immediately. The company expects head-to-head clinical results by summer 2026 and plans an FDA application to seek Medicare reimbursement in 2027.
1. John Farlinger Named CEO and Chairman
John Farlinger, formerly chair of the audit committee, was appointed CEO and chairman effective March 18, 2026. He received 3,700,000 stock options exercisable at $0.055 per share, with 50% vesting immediately and the remainder under the company’s standard plan, expiring five years after grant.
2. Clinical Milestones and FDA Application
Telo Genomics intends to report head-to-head clinical study results of its telomere-based oncology tests by summer 2026. In parallel, the company is preparing an FDA application aimed at securing Medicare reimbursement approval by 2027, targeting market leadership in multiple myeloma diagnostics.
3. Investor Relations Agreement with Sheridan Adams
The company engaged Sheridan Adams, LLC for investor relations consulting, paying $4,000 USD per month for six months plus 250,000 options at $0.05 per share vesting over 36 months and expiring five years after grant. The agreement aims to boost capital raising, trading volume, and institutional coverage.
4. Executive Chairman Resignation
Guido Baechler resigned as executive chairman and director effective March 31, 2026, and will continue advising the company. The board thanked him for his contributions during his tenure and looks to maintain continuity through new leadership and advisory support.